Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine

Executive Summary

The drug and diagnostic industries should partner, not merge, to develop companion products, according to a diagnostics industry representative on a recent Personalized Medicine Coalition conference panel
Advertisement

Related Content

Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
Companion Dx Pioneers Test Variety Of Business Models
New Business Models Needed For Drug Diagnostic Partnerships
Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study
Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study
Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study
Novartis Pharma To Add Diagnostics Unit In 2009
Roche Makes Early Headway With Pharmaco-Diagnostics

Topics

Advertisement
UsernamePublicRestriction

Register

PS050720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel